Serum parathyroid hormone (PTH) levels have been measured in 8 patients with hypercalcaemia associated with urological malignancy: 3 renal cell carcinomas, 2 adenocarcinomas of prostate, 2 transitional cell carcinomas of bladder and one transitional cell carcinoma of kidney. Five (63%) of these 8 patients had bone metastases. PTH was detectable in the serum of all 8 hypercalcaemic patients, but in only 2 cases was the PTH level above the normal range, and in one of these a coincidental parathyroid adenoma was found to be responsible for the hypercalcaemia. It appears that these tumours can produce a hormone-like substance with biological effects similar to PTH.
References
1.
RalstonSFogelmanIGardnerMD, Hypercalcaemia of malignancy and metastatic bone disease: Is there a causal link?Lancet1982; ii: 903–5
2.
CopeOBarnesBACastlemanBMuellerGCRothSI. Vicissitudes of parathyroid surgery trials of diagnoses and management of 51 patients with a variety of disorders. Ann Surg1961; 154: 491–508
3.
ChambersTJ. The pathobiology of the osteoclast. J Clin Pathol1985; 38: 241–52
4.
SeyberthHWSegreGVMorganJL. Prostaglandins as mediators of hypercalcaemia associated with certain types of cancer. N Engl J Med1975; 293: 1278–83
5.
TashjianAH. Role of prostaglandins in the production of hypercalcaemia by tumours. Cancer Res1978; 38: 4138–41
6.
BrennerDHarveyHALiptonADemersL. A study of prostaglandin E2 parathormone and responses to indomethacin in patients with hypercalcaemia and malignancy. Cancer1982; 49: 556–61
7.
HoriuchiNHolickMFPottsJTRosenblattM. A parathyroid hormone inhibitor in vivo: designed and biological evaluation of a hormone analog. Science1983; 220: 1053–5
